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A cure for type 1 diabetes in humans will prob-
ably require the provision or elicitation of new 
pancreatic islet  cells in conjunction with re-
establishment of immunological tolerance. Ser-
toli cells (SCs) are normally found in the testes, 
where they couple trophic effects with preven-
tion of immune damage to developing germ 
cells. SCs engraft and self-protect when trans-
planted into allogeneic and xenogeneic envi-
ronments (Emerich et al., 2003). In different 
settings, SCs manifest an ability to provide local 
immunoprotection to cografted tissues, includ-
ing those from xenogeneic donors (Shamekh   
et al., 2006). In murine type 1 diabetes, SCs pro-
tect cografted allogeneic and xenogeneic islets 
from immune destruction (Suarez-Pinzon et al., 
2000; Yang et al., 2002). Thus, SC might con-
fer immunoprotection for transplanted islets in 
humans, representing a possible means of over-
coming the major obstacle associated with cell 
therapy. In addition, porcine SC culture super-
natants mediate the homologous transdifferen-
tiation in vitro of neonatal pancreatic duct cells 
into endocrine cells (Basta et al., 2004).
SCs can be implanted into the central ner-
vous system to locally deliver molecules with 
trophic and antiinflammatory effects on the 
surrounding tissue (Sanberg et al., 1996). When 
SCs are grafted into an experimental model of 
Huntington’s disease, the beneficial effects are 
quite similar to those obtained by systemic treat-
ment with nonsteroidal antiinflammatory drugs 
(Emerich, 2004). SCs also provide protection 
in experimental models of Parkinson’s disease and 
amyotrophic lateral sclerosis (Sanberg et al., 1997; 
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Type I diabetes mellitus is caused by autoimmune destruction of pancreatic  cells, and 
effective treatment of the disease might require rescuing  cell function in a context of 
reinstalled immune tolerance. Sertoli cells (SCs) are found in the testes, where their main 
task is to provide local immunological protection and nourishment to developing germ cells. 
SCs engraft, self-protect, and coprotect allogeneic and xenogeneic grafts from immune 
destruction in different experimental settings. SCs have also been successfully implanted 
into the central nervous system to create a regulatory environment to the surrounding 
tissue which is trophic and counter-inflammatory. We report that isolated neonatal porcine 
SC, administered alone in highly biocompatible microcapsules, led to diabetes prevention 
and reversion in the respective 88 and 81% of overtly diabetic (nonobese diabetic [NOD]) 
mice, with no need for additional  cell or insulin therapy. The effect was associated with 
restoration of systemic immune tolerance and detection of functional pancreatic islets that 
consisted of glucose-responsive and insulin-secreting cells. Curative effects by SC were 
strictly dependent on efficient tryptophan metabolism in the xenografts, leading to TGF-–
dependent emergence of autoantigen-specific regulatory T cells and recovery of  cell 
function in the diabetic recipients.
© 2009 Fallarino et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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islets from long-term survivors were, indeed, all of host ori-
gin, indicating that the diabetic NOD mice actually retain 
substantial  cell mass, which can be reconditioned to reverse 
disease upon adjuvant-dependent dampening of autoimmu-
nity (Kodama et al., 2003; Nishio et al., 2006).
In the present study, we aimed at revitalizing pancreatic 
islet  cells in NOD mice by means of the trophic and immuno-
regulatory effects of neonatal porcine SC administered alone in 
highly biocompatible alginate microcapsules. In these con-
ditions, the grafted SCs remain viable and functional for re-
markably long periods of times (Luca et al., 2007). We obtained 
evidence that IDO-expressing xenogeneic SC could represent 
a novel form of cell therapy in NOD mice, combining control 
of autoimmunity and emergence of T reg cell responses with 
pancreas regeneration from adult multipotent progenitor cells.
RESULTS
Prevention and reversion of diabetes by SC xenografts
Severely diabetic NOD mice (blood glucose levels of 350–
400 mg/dl for at least 10 d) were transplanted on day 0 with 
empty capsules (ECs; n = 18) or encapsulated SC (n = 21). 
All recipients of EC developed progressive disease, with sur-
vival times of 28–62 d. Four recipients of SC died within 
60–90 d of transplantation, although 17 of 21 (81%) became 
long-term survivors (>120 d), and 10 of those became nor-
moglycemic (Fig. 1, A and B; Table I). The percentage of 
Luca et al., 2007). Although these data do not clarify the un-
derlying mechanisms, they do suggest that the graft of SCs 
alone may exert beneficial effects on specific tissues through 
their ability to provide trophic effects and/or modulation of 
pathogenic inflammation.
The nonobese diabetic (NOD) strain of mice has become 
a prototypic model of autoimmune disease (Delovitch and 
Singh, 1997; Atkinson and Leiter, 1999). A large proportion of 
female mice generally dies of type 1 diabetes, reflecting the 
onset of severe insulitis at 4 wk of age and the T cell–medi-
ated destruction of pancreatic  cells. The predisposition of 
NOD mice to develop autoimmunity is the result of defects in 
both peripheral and central tolerance mechanisms (Kishimoto 
and Sprent, 2001). Several abnormalities have been described 
in those mice, including aberrant APC function (Serreze et al., 
1993) and impaired activity of the immunosuppressive enzyme 
indoleamine 2,3-dioxygenase (IDO; Grohmann et al., 2003a; 
Fallarino et al., 2004), whose effects are typically linked to the 
generation and function of regulatory T (T reg) cells in the pe-
riphery (Puccetti and Grohmann, 2007).
In different experimental settings, immunological reversal 
of autoimmune diabetes does not require externally provided 
 cell precursors, suggesting that control of the autoimmune 
disease at a crucial time in diabetogenesis can result in recov-
ery of  cell function (reversion rates of 30–41%; Chong et al., 
2006; Suri et al., 2006). In one such study, the recovered   
Table I.  Effect of SC xenografts on course of disease in overtly diabetic mice
Number Mouse ID Age at 
onset
Maximum BG before 
transplantation
BG 1 wk after 
transplantation
BG 2 wk after 
transplantation
BG < 250 mg/dl after 
transplantation
Survival after 
transplantation
wk mg/dl mg/dl d d
1 A4 12 447 345 216 >106 >120
2 A17 12 362 244 143 >113 >120
3 B8 14 424 >500 >500 NA 60
4 A32 14 498 >500 >500 NA 60
5 C13 16 321 216 165 >113 >120
6 B44 14 390 234 230 >113 >120
7 D78 16 420 320 211 >100 >120
8 C25 15 480 289 197 >106 >120
9 B40 16 420 320 188 >106 >120
10 A98 14 370 310 206 >106 >120
11 A23 14 390 238 212 >113 >120
12 C39 14 402 330 200 >106 >120
13 C36 16 346 >500 >500 NA 60
14 A14 14 360 308 488 NA 90
15 B24 14 350 211 192 >113 >120
16 C12 15 330 225 184 >113 >120
17 A29 15 >500 242 188 >113 >120
18 D30 15 >500 493 227 >106 >120
19 C50 15 >500 375 218 >106 >120
20 B63 15 470 500 244 >106 >120
21 C56 15 >500 321 201 >106 >120
Severely diabetic recipient mice received 2 × 107 encapsulated SCs, to be monitored for blood glucose (BG) concentrations over time and survival. 10 mice (not indicated in the 
table) became stably normoglycemic (blood glucose < 200 mg/dl).JEM VOL. 206, October 26, 2009 
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Figure 1.  Effects of treatment with encapsulated SC on disease progression and pancreatic histology in diabetic NOD mice. (A) Kaplan-Meier 
plot for survival. Diabetic NOD females were treated with an implant of EC or SC, and survival probability was plotted over time. Data are from 18 and 21 
animals that received EC or SC. P < 0.001 for comparison between the two treatment groups. (B) Blood glucose concentrations in three NOD recipients 
successfully treated with SC (for mouse ID, see Table I). (C) Pancreatic histology. Three mice (Numbers 2, 7, and 15) were killed 18 wk after grafting. Sec-
tions of the pancreata were stained with hematoxylin and eosin, showing both islets (mostly periductal; indicated by arrows) free of infiltrate and islets 
with innocuous-looking infiltrates and no signs of invasive insulitis. Prediabetic and age-matched diabetic controls are shown for comparison (indicated). 
Bars, 100 µm. (D) Islets from hyperglycemic control or SC-treated mice (n = 3) were scored at different weeks after transplant (on time 0), and percent-
ages were recorded that represent numbers of islets of a given score over total number of islets (30–40 per pancreas). Control mice (top) were either 
sham-transplanted or transplanted with EC. Each experiment was repeated with reproducible results two to four times and one representative experiment 
is shown in each panel.2514 IDO+ SERTOLI CELLS REVERT AUTOIMMUNE DIABETES | Fallarino et al.
Cure by SC xenografts is associated with the emergence  
of a regulatory environment
In sorted CD4+ cells from pancreatic LNs (PLNs) of mice re-
ceiving SC therapy, flow cytometry analysis revealed signifi-
cantly increased expression of Foxp3 (T reg cell specification 
factor) relative to controls (Fig. 2 A). This was reflected in 
the spleen by changes in the expression of the T reg markers 
CTLA-4 and glucocorticoid-inducible TNF receptor (GITR; 
Fig. 2 A). Upon immunofluorescence analysis, CD4+ Foxp3+ 
cells characterized the still insulitic pancreata of mice treated 
with SC for 2–3 wk relative to controls (Fig. 2 B). In sorted 
PLN CD3+ T cells from diabetic mice, SC therapy caused a 
>100-fold reduction in message expression of Rorc (encoding 
the Th17 transcription factor ROR-t), as well as strong in-
duction (>50-fold) of Foxp3 (Fig. 3).
The antigen specificity of the T reg activity induced by 
SC graft was examined in terms of T cell response to fusion 
proteins encompassing proinsulin-related P3UmPI, glutamic 
acid decarboxylase (GAD)–related P3UmG, or IA-2–related 
P3UhIA domains (Fig. S3, A and B). Proliferative responses 
were measured in pancreatic CD4+CD25+ and CD4+CD25 
cells from SC-treated NOD mice, stimulated with individ-
ual fusion proteins. In addition, inhibition of CD4+CD25 
cells from diabetic NOD mice by antigen-specific CD4+ 
CD25+ cells from SC-treated mice was also investigated. 
disease-free animals rose to 88% (22 out of 25) when the SCs 
were administered to prediabetic mice that were 8–10 wk of 
age, with glucose levels <200 mg/dl (Fig. S1 depicts a Kaplan-
Meier plot for normoglycemia, in which P < 0.001 for com-
parison between EC and SC treatment groups).
The diabetic mice on SC therapy that developed a slower 
but progressive disease exhibited the occurrence of insulin-
producing pancreatic islet cells without invasive insulitis (that 
is, autoreactive cells within the islets, as seen in the EC recip-
ients) but with pronounced peri-insulitis (circumferential 
lymphoid cells that did not progress, for the most part, to in-
vasion). In contrast, in the pancreata of mice on successful SC 
therapy, reappearance of islets occurred without invasive in-
sulitis and with minimal or no peri-insulitis that decreased 
over time (Fig. 1, C and D).
18 wk after SC treatment, the mean number of islets in 
the pancreas was 20.7 ± 3.6 (mean ± SD; n = 5), a number 
not significantly different from that in prediabetic controls 
(25.8 ± 4.5; P = 0.081). The mean area of individual islets 
from successfully treated mice was 2,326 ± 470 µm2 (of 
which 55% stained positive for insulin), which represents 
roughly one-third of the corresponding value in a prediabetic 
control. 3 of the 10 mice that became normoglycemic after 
SC therapy were subjected to intraperitoneal glucose testing, 
displaying nearly normal responses (Fig. S2).
Figure 2.  Induction of a regulatory response by xenogeneic SC in diabetic mice. (A) Cytofluorometric analyses of Foxp3, CTLA-4, and GITR expres-
sion in CD4+ cells from spleens (left) or PLN (right) of mice (n = 3) treated with EC or SC for 1–3 wk. Isotype controls were included in all assays for nor-
malization, and dot plots were gated on CD4+ cells. Preimplant percentages of double-positive cells for each marker (at week 0) are shown at the top. Line 
graphs depict fold changes (mean and SD from three experiments) in normalized marker expression from SC-treated mice relative to control counterparts 
on EC treatment (in which fold change = 1). Error bars indicate SD. *, P < 0.05–0.01. (B) The peri-islet infiltrate observed by immunofluorescence analysis 
in successfully treated NOD mice consisted of CD4+ cells, of which 20% expressed Foxp3, the transcriptional factor associated with T reg cells. Islets 
from normoglycemic NOD mice were characterized by intense lymphocytic peri-islet infiltrates, which is consistent with a nonprogressive insulitis (not 
depicted). Arrows indicate double-positive cells (>50% peri-insular Foxp3/CD4 cells, as opposed to <2% intrainsular in EC-treated controls). Bars, 50 µm.JEM VOL. 206, October 26, 2009 
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versial role in regulating pathogenetic Th17 cells (Jankovic 
and Trinchieri, 2007). In NOD mice, IFN- induced by ad-
juvant-free antigen restores normoglycemia through inhibi-
tion of IL-17 (Jain et al., 2008). Both in vitro and in vivo, 
differentiation of the Th17 lineage requires up-regulation of 
ROR-t (Yang et al., 2008), and evidence indicates that 
TGF-–induced Foxp3 inhibits Th17 cell differentiation by 
antagonizing ROR-t function (Zhou et al., 2008).
We measured IL-17, IL-23, and TGF- in the splenic 
CD4+ and/or pancreatic leukocyte fractions of diabetic mice 
treated with SC or EC for 6 wk, together with IL-6, IL-10, 
IFN-, and IL-4 in the spleen and/or pancreas (Fig. 4 A). SC 
therapy strongly opposed IL-23 and IL-17 productions both 
in the spleen and pancreas of diabetic mice. Reduced pro-
duction was also observed for IL-6, IL-10, and IFN-, mostly 
in the pancreas. Although present in control animals on EC, 
The results showed that effector T cells from EC-treated di-
abetic mice proliferated vigorously in response to each auto-
antigen, and so did the regulatory cells from SC-treated mice 
(P3UmG ≥ P3UmPI > P3UhIA). However, these in vitro–
expanded  T  reg  cells  of  single  antigen  specificities  were 
poorly capable of inhibiting the polyclonal anti-CD3–stimu-
lated effector population.
Effective SC therapy alters the local pancreatic  
as well as systemic cytokine milieu
Th17 cells promote autoimmunity in mice and have been 
implicated in the pathogenesis of human inflammatory dis-
eases (Laurence and O’Shea, 2007). Differentiation of pro-
inflammatory Th17 cells requires IL-23. In vitro, however, 
Th17 differentiation is independent of IL-23 and is induced 
by TGF- plus IL-6 or IL-21, with IL-10 having a contro-
Figure 3.  In diabetic NOD mice, SC therapy causes reduced expression of the ROR-t–encoding gene and augmentation of Foxp3, with 
negligible effects on Tbet and Gata3. Rorc, Foxp3, Tbet, and Gata3 transcripts were evaluated in CD3+ T cells from PLN of mice treated with EC or SC 
for 3–4 wk. 5 × 105/ml of sorted CD3+ lymphocytes were activated with 1 µg/ml anti-CD3 for 24 h. Rorc, Foxp3, Tbet, and Gata3 mRNAs were quantified 
by real-time PCR using Gapdh normalization. Data (means ± SD from three experiments) are presented as fold change in normalized transcript expression 
in mice grafted with EC or SC relative to prediabetic 4-wk-old controls (in which fold change = 1; dotted line).2516 IDO+ SERTOLI CELLS REVERT AUTOIMMUNE DIABETES | Fallarino et al.
The response initiated by SC requires TGF-  
and can be adoptively transferred
Clonotypic T cell NOD mice expressing the BDC2.5–TCR-
 transgene (BDC2.5/NOD) are characterized by a preva-
lent population of pathogenetic CD4+ T cells that recognize 
an islet-related 12-mer peptide of GAD 65 (Katz et al., 1993; 
Judkowski et al., 2001; Quinn et al., 2001). Most BDC2.5/
TGF- was greatly increased by SC therapy. When chal-
lenged with the proinsulin-related fusion protein P3UmPI, 
CD4+CD25+  (but  not  CD25)  cells  in  PLNs  from  SC-
treated mice produced noticeable amounts of TGF-, as 
detected by intracellular staining. In EC-treated mice, pre-
ponderant production of IL-17A was observed in parallel, 
mostly by the CD4+CD25 fraction (Fig. 4 B).
Figure 4.  Effects of SC therapy on cytokine secretion profile of Th cells from diabetic mice. (A) Sorted CD4+ T cells from spleens (Sp) or PLNs, as 
well as unfractionated pancreatic-infiltrating leukocytes (PIL), were assayed for cytokine release in response to 1 µg/ml anti-CD3 after SC or control EC 
therapy. Data are means ± SD from four experiments. *, P < 0.001–0.01; **, P < 0.05. (B) Intracellular TGF- and IL-17A staining profiles of CD4+CD25+ 
and CD4+CD25 cells from SC-treated NOD mice upon in vitro stimulation with proinsulin-related P3UmPI or control OVA. Percentages of double-positive 
cells are shown in the top right quadrants. One experiment is shown representative of three.JEM VOL. 206, October 26, 2009 
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immunoblot analysis at 3–7 d of culture, as well as in SC re-
covered from successfully treated mice (Fig. 6 B). Functional 
IDO expression in those cells was demonstrable in vitro, in 
terms of tryptophan conversion to kynurenine, and this was 
negated either by adding a synthetic substrate competitor (i.e., 
1-methyl-tryptophan)  or  by  stably  silencing  IDO-encoding 
transcript expression by small interfering (si) mRNA technol-
ogy (Fig. 6 C). In contrast to control SC, cells with silenced 
IDO expression failed to protect hosts from diabetes develop-
ment (Fig. 6 D; Fig. S5 provides data on silencing efficiency by 
immunoblot and immunofluorescence analyses).
Gene expression pattern and insulin production in islets 
from SC-treated mice
In different diabetes models, both  cell proliferation and 
neogenesis contribute to restoration of  cell function. Early 
proliferation of host residual  cells did not appear to occur 
to a significant extent in NOD recipients of SC (Fig. S6). In 
pancreas regeneration, multipotent precursor cells proliferate 
and differentiate to form pancreatic islets. Among the numer-
ous genes that orchestrate their expression, Pdx1 is detected 
early (Hardikar, 2004). Using an experimental injury model 
of the pancreas, Xu et al. (2008) reported the involvement of 
Ngn3 (neurogenin 3), a marker for embryonic-type endo-
crine progenitor cells, in the formation of new insulin-pro-
ducing  cells. These Ngn3+ facultative endocrine progenitor 
cells in the adult pancreas could be of potential value in the 
provision or elicitation of new pancreatic islet  cells once 
the underlying immune disease has been eliminated.
After the implant of EC or SC in diabetic mice, we mea-
sured pancreatic Pdx1, Ngn3, and c-kit transcript expression 
(all considered to be markers of progenitor cells) together 
with transcripts specific for Neurod1, Nkx6.1, Pax4, and Pax6, 
which are known to encode transcription factors downstream 
of Ngn3 in the differentiation cascade and which result in 
predominant  cell,  cell (Pax4), or  cell (Pax6) develop-
ment (Fig. 7 A). With the exception of Nkx6.1, Pax4, and 
Pax6, whose expression was marginally or not affected at all, 
onset of diabetes increased pancreatic gene expression by it-
self (>10-fold increase relative to prediabetic mice [in which 
fold change = 1], perhaps reflecting a self-repair attempt by 
the damaged islets), most notably, Ngn3. Grafting diabetic 
mice with SC resulted, however, in fold increases ranging 
from 8–15 (Pax4, Pax6, and Nkx6.1) to 30–60 (c-kit, Pdx1, 
Ngn3, and Neurod1).
Immunoblot analysis of Ngn3 expression in diabetic mice 
grafted with EC or SC for different times revealed progres-
sively increasing expressions of the transcriptional regulator   
in mice cured by SC therapy, with peak levels at 2–4 wk of 
treatment (Fig. 7 B). In contrast, in control mice on EC treat-
ment, detection of the protein at diabetes onset was accompa-
nied by persistent yet low levels. Serum insulin levels at 6–8 wk 
of treatment suggested recovery of  cell function (Fig. S7). 
Immunofluorescence analysis revealed that the increased Ngn3 
expression induced by effective therapy was accompanied   
by an ability of the islets to produce insulin, glucagon, and 
NOD mice do not develop spontaneous diabetes but do de-
velop insulitis accompanied by the appearance of activated 
islet-specific T cells. Evidence suggests that these cells are 
actively  prevented  from  causing  disease  by  a  CTLA-4– 
dependent immunoregulatory mechanism and by the action 
of CD4+CD25+CD69 T reg cells (Herman et al., 2004). At 
variance with BDC2.5/NOD mice, BDC2.5 TCR trans-
genic mice backcrossed into the NOD-SCID background 
show fulminant diabetes (Kurrer et al., 1997). Rapid diabetes 
also  develops  in  NOD-SCID  mice  adoptively  transferred 
with spleen cells or purified CD4+ T cells from BDC2.5/
NOD donors (You et al., 2004). In this setting, however, 
onset of disease is prevented by the cotransfer of CD4+CD25+ 
CD62L+ cells from prediabetic NOD mice (You et al., 2004) 
or of T reg cells generated in vitro by tryptophan catabolites 
(Fallarino et al., 2006).
Using this cotransfer model, we obtained evidence that 
pancreatic CD4+ cells from SC-treated mice were capable of 
protecting NOD-SCID mice from the induction of diabetes 
by BDC2.5 transgenic T cells (Fig. 5 A). Protection from di-
abetes was also demonstrable on transfer of splenocytes from 
diabetic NOD/Mrk mice injected in combination with 
CD4+ cells from SC-treated mice (Fig. 5 B). Similar to previ-
ous results in other models (Suarez-Pinzon et al., 2000; Belghith 
et al., 2003), TGF- had an indispensable role in the induc-
tion of the autoimmune-preventive cell-transferable regulatory 
response initiated by SC in NOD mice (P < 0.001; Fig. 5 C). 
No significant effect was instead afforded by the in vivo ad-
ministration  of  anti–IL-10,  anti-GITR,  or  anti–CTLA-4, 
though a trend toward worsening of the disease was associ-
ated with CTLA-4 neutralization (P = 0.522; Fig. 5 C). Nei-
ther TGF- nor CTLA-4 was required for diabetes reversal 
in the recipients of an adoptively transferred protective CD4+ 
T cell response (Fig. 5, A and B). Depleting CD4+ cells of the 
CD25+ fraction in both models abrogated transfer of protec-
tion (unpublished data).
In  contrast,  purified  CD4+CD25+  cells  cultured  with 
dendritic cells presenting multiple autoantigen-related fusion 
protein epitopes greatly suppressed the proliferation of CD4+ 
CD25 from diabetic donors in a TGF-–independent fash-
ion (Fig. 5 D; P = 0.543). Thus, TGF- was required for the 
generation and/or expansion, but not effector function, of   
T reg cells in SC-treated NOD mice.
IDO expression by SC is instrumental  
in their therapeutic efficacy
IDO is an immune regulatory enzyme that fosters the genera-
tion or activation of IL-10–producing T reg cells (Mellor and 
Munn, 2004; Puccetti and Grohmann, 2007). We investigated 
IDO expression by SC and the possible contribution of IDO-
dependent immune regulation by SCs to their therapeutic ac-
tivity in diabetic mice. In contrast to freshly harvested cells, SC 
differentiating in vitro progressively acquired messenger RNA 
(mRNA) predictably encoding IDO (Fig. 6 A and Fig. S4). 
Detection of IDO protein by cross-reactive rabbit anti–mouse 
and mouse anti–human IDO reagents did indeed occur on   2518 IDO+ SERTOLI CELLS REVERT AUTOIMMUNE DIABETES | Fallarino et al.
Figure 5.  Induction but not effector phase of protection by SC xenografts requires TGF- and is cell transferable to NOD-SCID recipients. 
(A) 106 8–12-wk-old NOD/BDC2.5 splenocytes were injected intravenously alone (control [C]) or in combination with 106 sorted PLN CD4+ cells from NOD 
mice implanted with EC (EC/CD4) or SC (SC/CD4) for 3 wk. Groups of SC/CD4–treated mice were given anti–TGF- (mouse IgG2b 1D11), anti–CTLA-4 
(hamster IgG 4F10; either antibody at 0.5 mg/mouse twice weekly for 3 wk), or the respective control antibodies (not depicted). The incidence of diabetes 
in the NOD-SCID recipients is indicated over time for the different groups (n = 10), as revealed by glycosuria and hyperglycemia (P < 0.001, SC versus EC 
or no treatment). (B) Protection from diabetes was also studied by transfer of splenocytes (5 × 106) from diabetic NOD/Mrk mice injected alone (control 
[C]) or in combination with 106 sorted PLN CD4+ cells from NOD mice implanted with EC (EC/CD4) or SC (SC/CD4) for 3 wk. Additional groups included 
anti–TGF- or anti–CTLA-4 treatments as in A. The incidence of diabetes in the NOD-SCID recipients is indicated over time for the different groups (n = 10), 
as revealed by glycosuria and hyperglycemia (P < 0.001, SC versus EC or no treatment). (C) The regulatory response initiated by implanted SC requires 
TGF- for induction in the primary host. NOD recipients of protective SC implants were treated with TGF-–neutralizing monoclonal 1D11 (0.5 mg/mouse 
twice weekly for 3 wk) or the isotype control, and the incidence of diabetes was monitored over time (n = 10). Additional experimental groups received 
treatments (0.5 mg/mouse, twice weekly for 3 wk) with anti–IL-10 (JES5.2A5; rat IgG1), anti–CTLA-4 (4F10), or anti-GITR (DTA-1; rat IgG2b; in alternative, 
rat/hamster control IgG antibodies; not depicted). P < 0.001, for anti–TGF- versus control treatment. The percentages of pancreatic Foxp3+ cells in the 
CD25+ fraction were 35% in the EC group, 62% in SC-treated mice, and 29% in the latter group on additional anti–TGF-. (D) Purified CD4+CD25+ T cells 
from SC-treated NOD mice were cultured for 3 d with fusion protein–pulsed splenic CD11c+ cells as antigen-presenting cells (a mixture of proinsulin-
related P3UmPI, GAD-related P3UmG, and IA-2-related P3UhIA). The recovered T cells were assayed (at the different regulatory/effector cell ratios indi-
cated) for suppression of 72-h proliferation in CFSE-labeled CD4+CD25 cells from diabetic donor mice. In selected cultures, control (mouse IgG2b) or 
anti–TGF- antibody was added. Controls included CFSE-labeled CD4+CD25 cells cultured in the absence of the regulatory fraction and/or anti-CD3. The 
percentages of red-marked proliferating cells are shown. The corresponding percentages of control CD4+CD25 cells cultured with OVA-primed 
CD4+CD25+ T cells from SC-treated mice or with P3UmPI/P3UmG/P3UhIA–primed CD4+CD25+ T cells were consistently in the 85–90% range (see also Fig. 
S3 B). One experiment is shown representative of three.JEM VOL. 206, October 26, 2009 
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Figure 6.  IDO expression by SC is instrumental in their therapeutic efficacy. (A) In vitro differentiation of SC progressively increases mRNA puta-
tively encoding porcine IDO. SCs were cultured for 3, 5, or 7 d, and IDO-encoding mRNA was analyzed by real-time PCR with -actin transcript normaliza-
tion. Data (mean values and SD from four independent experiments) are presented as fold change in normalized transcript expression in cultured SC relative 
to freshly harvested cells (in which fold change = 1; dashed line). (B) Detection of predicted IDO protein by immunoblot with rabbit anti–mouse or mouse 
anti–human IDO. Freshly harvested SCs (day 0), as well as cells cultured in vitro for 3 or 7 d, were analyzed using -actin normalization. SCs were also re-
covered from successfully treated mice (ex vivo) and assayed with the anti–human reagent. Indo-transfected (+) and mock-transfected () P1.HTR cells 
were assayed in combination with anti–murine IDO as the respective positive and negative controls. Human HeLa cells, treated (+) or not () with IFN-  
(a transcriptional inducer of INDO), were a second pair of controls used in combination with the anti–human reagent. Note that with both reagents the 
mature form of the protein was detected as a doublet (this has been described for human IDO as well). One experiment is shown representative of three.  
(C) Functional IDO expression by either freshly harvested SC (day 0) or cells cultured in vitro for 3 or 7 d. SCs were also recovered from successfully treated 
mice (ex vivo) and assayed for functional IDO expression. Treatments included cell exposure in vitro to the IDO inhibitor 1-methyl-tryptophan (1-MT) or 
silencing IDO-encoding transcripts by siRNA technology. Nc siRNA represents the negative control treatment. Enzyme activity (means ± SD; n = 4) was 
measured in terms of the ability of SC (3 × 106/ml) to metabolize tryptophan to kynurenine, measured by high-performance liquid chromatography.  
(D) Kaplan-Meier plot for survival in diabetic mice receiving SC with silenced IDO-encoding mRNA expression. Control indicates diabetic mice on EC treatment. 
Nc, negative control. P < 0.001 for comparison between the control and IDO siRNA treatment groups. One experiment is shown representative of three.2520 IDO+ SERTOLI CELLS REVERT AUTOIMMUNE DIABETES | Fallarino et al.
Figure 7.  Gene expression pattern and insulin production in islets from successfully treated mice. (A) Real-time PCR analysis of pancreatic gene 
expression in diabetic mice treated with EC or SC for 2 wk. SCs were treated with either IDO siRNA or negative control (nc) siRNA. mRNA was extracted 
from digested pancreata and genes encoding factors were examined that initiate (Ngn3) or contribute to islet cell differentiation. Data (mean values ± SD 
from three experiments) are presented as fold change in normalized transcript expression in pancreata from diabetic mice on EC or SC therapy relative to 
prediabetic 4-wk-old controls (in which fold change = 1; dashed lines). (B) Immunoblot analysis of Ngn3 expression in diabetic mice grafted with EC or 
SC for different times. Pancreas tissue extracts from age-matched untreated mice (diabetic), as well as transplanted hosts over time, were reacted with 
Ngn3 A-19 affinity-purified goat polyclonal antibody, using -actin normalization. Prediabetic mice were included as a control (indicated as such), to-
gether with sham-transplanted mice at 2 wk (there were no survivors at 16 wk among the EC recipients). One experiment is shown representative of 
three. Using scanning densitometry analysis and mean values from the three experiments, the differences between the EC and SC treatment groups were 
significant at both 2 wk (P = 0.006) and 4 wk (P = 0.009). (C) Immunostaining for insulin, glucagon, and somatostatin in islets from three successfully 
treated mice. Frozen pancreatic sections from diabetic controls and SC-treated mice (indicated) were post-fixed with formaldehyde, and fluorescent im-
ages, in which nuclei had been stained with DAPI (blue), were acquired by light microscopy. Bars, 50 µm. One experiment is shown representative of three.JEM VOL. 206, October 26, 2009 
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somatostatin (Fig. 7 C). Notably, the occurrence of glucagon 
and somatostatin double-stained cells would apparently reca-
pitulate the process of embryonic stem cell development and, 
thus, be indicative of authentic regeneration.
DISCUSSION
Cell therapy is a potentially powerful tool in the treatment of 
many grave disorders including leukemia, immune deficien-
cies, autoimmune diseases, and diabetes. Bone marrow mesen-
chymal stem cells have potent immunosuppressive properties 
and have been advocated for IDO-dependent control of in-
flammatory diseases in humans (Matysiak et al., 2008). In dif-
ferent experimental settings, mesenchymal stem cells do, 
indeed, exploit the IDO mechanism for tolerogenesis (Haniffa 
et al., 2007; Jones et al., 2007; Matysiak et al., 2008). Like bone 
marrow–derived mesenchymal stem cells, which are multipo-
tent adult stem cells, SCs are of mesodermal origin, and mRNA 
expression and protein secretion of mesenchymal markers have 
been found in rat SCs in addition to stem cell factor (c-kit li-
gand) and other products, which contribute to maintaining the 
spermatogonial stem cell niche (Konrad et al., 2005).
Among the latter, immature pig SCs secrete IGF-1 (insu-
lin-like growth factor 1), which is crucially involved in regu-
lating  cell growth (Luca et al., 2007). Porcine c-kit ligand 
and IGF-1 have 82% and >80% protein identity with their 
respective mouse counterparts. Our unpublished observations 
with cultured SC demonstrated IGF-1 production by RIA 
testing and c-kit ligand expression by PCR analysis. Encap-
sulated cells maintained both expressions. Although FasL has 
also been reported to be expressed by SC (Yao et al., 2007), 
cultured SCs do not secrete soluble forms of FasL (Riccioli 
et al., 2000).
Administration of SCs across xenogeneic barriers induces 
transplantation tolerance without altering systemic immune 
competence, and SC could be used as a novel and potentially 
powerful tool in cell transplantation therapy and for protec-
tion of transplanted adult or embryonic stem cells (Shamekh 
et al., 2006). In this study, we tested the hypothesis that a 
peculiar combination of self-protective, immunoregulatory, 
and trophic properties might confer a unique potential for 
type 1 diabetes therapy on SC, with no absolute need for the 
cotransfer of allogeneic or surrogate stem cell–derived  cells 
or insulin therapy.
We obtained evidence that (a) porcine SCs are competent 
at  eliciting  functional  pancreatic  islets  in  severely  diabetic 
NOD mice, reversing disease in a remarkably high percent-
age of recipient hosts; (b) the immunoregulatory component 
of SC activity is dependent on the tolerogenic effects of tryp-
tophan catabolism, initiated in the host by SC xenografts, such 
that restoration of the kynurenine pathway (Puccetti and 
Grohmann, 2007; Romani et al., 2008a) by SC could repre-
sent a new form of immunotherapy in autoimmune diabetes; 
and (c) SC might effectively combine the advantages of mes-
enchymal cells (which are also IDO-positive and immuno-
regulatory yet lack trophic effects) with those of maneuvers 
that foster  cell regeneration but lack substantial impact on 
the underlying autoimmune condition, linking IL-17 antag-
onism (Jain et al., 2008) and emergence of T reg responses 
(Zhou et al., 2008) with pancreas regeneration from adult 
multipotent progenitor cells (Xu et al., 2008).
In fact, we obtained data showing that autoimmunity as a 
whole is suppressed in NOD recipients of SC, including on-
set of thyroiditis (unpublished data). Similarly, we attempted 
to  determine  whether  encapsulated  SCs  are  protective  in 
other experimental models of autoimmunity. In experiments 
parallel to those in NOD mice, we have obtained preliminary 
evidence that SC can protect against experimental autoim-
mune encephalomyelitis, in a model system which we have 
previously described in detail and which makes use of suscep-
tible strains of mice immunized with the encephalitogenic 
MOG peptide (Orabona et al., 2005). In this setting, IDO-
dependent mechanisms are, indeed, highly protective (Orabona 
et al., 2006; Matysiak et al., 2008).
Human islets may produce IDO themselves, and it has 
been suggested that in the short term, IDO activation could 
physiologically protect islets from cytotoxic damage (Sarkar 
et al., 2007). This is consistent with previous observations on 
the protective role of IDO (Grohmann et al., 2003a) and IDO-
inducing maneuvers in NOD mice (Alexander et al., 2002; 
Fallarino et al., 2004; Ueno et al., 2007), and with resistance 
of pancreatic islets to the direct effects of the IDO-induced 
general control nonderepressible 2 kinase stress pathway (Jalili 
et al., 2009). We became interested in evaluating whether the 
administration of natural (Romani et al., 2008a) or synthetic 
tryptophan catabolites (Platten et al., 2005) to NOD mice would 
be as protective as SC therapy. Although a detailed account 
of this study will be the subject of a subsequent paper, our 
preliminary data demonstrate that, consistent with the con-
cept that the therapeutic efficacy of SC results from a combi-
nation of immunoregulatory and trophic effects, supplemental 
kynurenines have only partial effects, i.e., those related to 
immunoregulation. Optimal exploitation of supplemental 
kynurenine therapy requires synergic effects by additional 
maneuvers, at least in severely diabetic mice.
Accumulating evidence points to the  cell itself as the 
most promising source for generating new  cells, and differ-
ent maneuvers may stimulate islet precursor cells to undergo 
neogenesis or to induce replication of existing  cells, empha-
sizing the importance of pancreas-resident stem or progenitor 
cells in islet regeneration (Xu et al., 2008). Expansion of  cell 
mass from endogenous sources, either in vivo or in vitro, rep-
resents an area of increasing interest. In vitro, one potential 
source of islet progenitors is the islet proper via the dediffer-
entiation, proliferation, and redifferentiation of facultative pro-
genitors residing within the islet. Recently, short-term treatment 
with a peptide fragment of INGAP (islet neogenesis-associ-
ated protein) was found to induce adult human pancreatic islet-
derived proliferative duct-like components to reform islet-like 
structures, which resembled freshly isolated islets with respect 
to the frequency and distribution of the four endocrine cell 
types, islet gene expression and hormone production, insulin 
content, and glucose-responsive insulin secretion (Hanley and 2522 IDO+ SERTOLI CELLS REVERT AUTOIMMUNE DIABETES | Fallarino et al.
lymphopenic hosts after conversion into Th1 cells (Martin-
Orozco et al., 2009). NOD-SCID mice, recipient of BDC2.5 
transgenic CD4+ cells matured to a Th17 phenotype, devel-
oped rapid onset of diabetes with extensive insulitic lesions, 
which progressed to overt disease in concurrence with the 
appearance of a strong IFN- response. However, at the pre-
diabetic stage, IFN- induced by an adjuvant-free antigen 
restores normoglycemia, most likely by localized bystander 
suppression of pathogenic IL-17–producing cells (Jain et al., 
2008). We found that SC therapy was associated with re-
duced production of IL-17A by CD4+CD25 cells in PLNs, 
which was concomitant with enhanced production of TGF- 
by the CD4+CD25+ counterpart.
IL-17 and IFN- show bidirectional influences with IDO 
regulation and function, and they influence each other through 
the IDO mechanism. Both IFN- (Grohmann et al., 2003a) 
and TGF- (Belladonna et al., 2008) are transcriptional acti-
vators of the gene encoding IDO, which is instead subject to 
IL-6–driven regulatory proteolysis (Orabona et al., 2008). The 
IDO mechanism initiates the peripheral TGF-–dependent 
generation of autoimmune-preventive T reg cells in NOD 
mice (Fallarino et al., 2006). Both T reg cell activity and kyn-
urenine products of tryptophan degradation oppose Th17 re-
sponses through down-regulation of Rorc transcription (Romani 
et al., 2008a,b). Thus, the immunoactive component of SC 
therapy in our model system may call for a staged response, which 
combines an early counter-inflammatory action of tryptophan 
catabolism (Grohmann et al., 2003b) with the generation of 
CTLA-4+ GITR+ T reg cells (Fallarino et al., 2006), which 
could then use the IDO mechanism as an effector system in 
the homeostatic regulation of peripheral immunity (Fallarino 
et al., 2003; Grohmann et al., 2007; Puccetti and Grohmann, 
2007). The early IDO-dependent tryptophan catabolizing ac-
tivity of the grafted SC appears to be indispensable for thera-
peutic activity. Analogous to several experimental settings of 
IDO-associated “infectious tolerance” (Belladonna et al., 2009), 
our data provide evidence that TGF- is required for the gen-
eration, but not the effector function, of T reg cells in SC-
treated NOD mice.
In conclusion, IDO, a “metabolic” enzyme conserved 
through the last 600 million years of evolution, suppresses T cell 
responses and promotes tolerance in mammalian pregnancy 
(Munn et al., 1998), as well as in autoimmune (Grohmann et al., 
2003a) and allergic (Grohmann et al., 2007) inflammation. Its 
regulation (Orabona et al., 2008), as well as the mechanisms of 
its action as an immune regulator, are composite (Belladonna 
et al., 2009) and include an arrest in T cell proliferation, in-
duction of Th cell apoptosis, reversible impairment of T cell 
activity through down-regulation of T cell receptor -chain, 
and the generation or activation of T reg cells (Mellor and 
Munn, 2004; Puccetti and Grohmann, 2007). Our current 
study provides evidence for effective therapy of experimental 
autoimmune diabetes by implants of IDO-expressing encap-
sulated SC, which likely act through multiple mechanisms, 
including  dampening  of  autoimmunity,  protection  and 
functional recovery of  cells, and neogenesis, as proven by 
Rosenberg, 2009). These studies emphasize how the plasticity 
of adult human islets may have significant implications for islet 
regeneration. Additionally, neogenesis or the budding of new 
islet cells from pancreatic ducts has been reported, although 
the existence and identity of a progenitor cell have been de-
bated (Inada et al., 2008).
In vivo, residual  cells that are present soon after onset of 
diabetes may respond to experimental regeneration (Reddy 
et al., 2008). In addition, combination therapy with glucagon-
like peptide 1 and gastrin restores normoglycemia in overtly 
diabetic NOD mice by increasing the pancreatic  cell mass 
and  down-regulating  the  autoimmune  response  (Suarez-
Pinzon et al., 2008). Suarez-Pinzon et al. (2000) had previ-
ously found that SC production of TGF-1, not Fas ligand, 
protects islet  cells from autoimmune destruction and 
TGF-1 diverts islet-infiltrating cells from a  cell–destructive 
(IFN-+) phenotype to a nondestructive (IL-4+) phenotype. 
We show in this paper that not only are xenogeneic SCs capa-
ble of sustained suppression of autoimmunity through TGF- 
induction of T reg cells and down-regulation of IL-17–depen-
dent responses but they are also competent at eliciting func-
tional pancreatic islet cells in the severely diabetic host, and 
they might do so by inducing neogenesis in periductal areas. 
The process does not require substantial replication of residual 
 cells and is instead associated with transcriptional activation 
of genes that are markers of progenitor cells and encode tran-
scription factors downstream of Ngn3 in the differentiation 
cascade of the four endocrine cell types (O’Neill et al., 2008). 
Islet gene expression correlated with hormone production, 
insulin content, and glucose-responsive insulin secretion, ac-
cording to developmental kinetics apparently reminiscent of 
the process of embryonic stem cell differentiation.
Castrated mice grafted with porcine immature SC mani-
fest an endocrine status and hormonal profiles suggestive of 
an intense cross-talk between the mouse hypothalamo–pitu-
itary axis, and the grafted porcine tissue, which reaches maxi-
mum amplification at 60 d after grafting (Kaneko et al., 
2008). Testicular SC dysfunction has recently been described 
in male patients with systemic lupus erythematosus, suggest-
ing a possible bidirectional link between SC function and 
onset of systemic autoimmunity (Suehiro et al., 2008). Anti-
androgen exposure in utero disrupts expression of insulin-
like factor 3 in the developing fetal rat testis (Brokken et al., 
2009). Finally, a stable SC line lacks the immunoprotective 
properties associated with primary SC in a model system of 
allogeneic islet transplantation (Dufour et al., 2008). It is 
therefore possible that multiple mechanisms participate in the 
SC-induced generation of an optimally trophic environment 
fostering  cell regeneration once autoimmunity has been 
dampened in NOD female mice by the suppressive proper-
ties of encapsulated SC. Although cultured SCs are compe-
tent  at  initiating  transdifferentiation  in  vitro  of  neonatal 
porcine pancreatic duct cells into endocrine cells (Basta et al., 
2004), further studies are needed to clarify this issue.
Recent evidence indicates that Th17 cells promote pan-
creatic inflammation but only induce diabetes efficiently in JEM VOL. 206, October 26, 2009 
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up-regulation of specific transcription factors, and/or transdif-
ferentiation. This may pave the way to the implementation of 
new forms of cell therapy for human diabetes, namely immuno-
therapy with cell types of nonhuman origin that would 
combine the advantages of mesenchymal cells with those of 
maneuvers that promote  cell regeneration but lack impact 
on the underlying autoimmune condition.
MATERIALS AND METHODS
Mice, pancreatic cell isolation, and histopathology. Female NOD/
Mrk mice, 4 and 12 wk of age, were purchased from Taconic. The mice 
were housed and fed under specific pathogen-free conditions. Autoimmune 
diabetes develops in 80% of NOD/Mrk female mice by 24 wk of age. 
Glycemia of <200 mg/dl (in the absence of glycosuria) and of 350–400 mg/dl 
(stably for at least 1 wk) in the presence of glycosuria defined prediabetes (5–
6 wk) and diabetes (>15 wk), respectively, at the time of SC transplantation 
(day 0). The NOD mice that were kept for 10 d with blood glucose levels 
of 350–400 mg/dl did change their weight significantly, and no insulin pel-
lets were necessary for survival. Transplanted mice were housed individually 
and blood glucose concentrations were monitored once a week up to day 
120. All in vivo studies were in compliance with national (Italian Approved 
Animal Welfare Assurance A-3143-01) and Perugia University Animal Care 
and Use Committee guidelines.
Pancreatic cell purification involved treating the organ with Complete 
Mini Protease inhibitors (Roche) followed by digestion with collagenase 
type IV (Sigma-Aldrich) in the presence of bovine pancreatic DNase (Sigma-
Aldrich) for 30–45 min at 37°C. The digested pancreata were further 
disrupted by gently pushing the tissue through a nylon screen, and pancre-
atic-infiltrating leukocytes were separated on a percoll gradient (Sigma- 
Aldrich). Purification of CD3+ or CD4+ T cell subsets from the spleen 
or LNs was conducted as previously described (Grohmann et al., 2007; 
Romani et al., 2008a).
For histopathology, 3–4 µm of paraffin-embedded sections of pancreata 
(five per organ) were stained with hematoxylin and eosin and analyzed by 
light microscopy. Insulitis scoring was according to the following criteria: 
severe insulitis, 50% or higher of the islet area is infiltrated; mild insulitis, 
<50% of the islet area is infiltrated; peri-insulitis, infiltration is restricted to 
the periphery of islets; and no insulitis, absence of cell infiltration.
Alginate-based microencapsulation of SC. Neonatal prepubertal large 
white pigs, 7–15 d of age, were used as SC donors. SCs were isolated, cultured, 
and alginate microcapsules were prepared by a dripping method, as previously 
described (Luca et al., 2007), resulting in the production of microcapsules mea-
suring 400–500 µm in equatorial diameter, with no loss of SC functional and 
morphological properties, either in vitro or in vivo, for extraordinarily long 
periods of time. Once implanted in the peritoneal cavity of NOD mice, the 
SC-containing capsules appear to be freely floating in the peritoneal cavity and 
morphologically intact, with the majority of them remaining free of fibrotic 
tissue overgrowth at 4 and 8 mo after transplant. When the capsules were ex-
planted at 8 mo of grafting, the embodied SCs were extraordinarily viable and 
appeared to be organized in tubule-like structures. Freshly harvested SCs, with 
the typical morphological and secretory features of somatic testicular cells from 
immature donors (Chatelain et al., 1987; Suarez-Pinzon et al., 2000; Yang   
et al., 2002; Mancuso et al., 2006), were differentiated in vitro for 5–7 d, and 
each mouse received a single intraperitoneal implant of encapsulated neonatal 
SC (2 × 107) through a small abdominal incision, as previously described (Luca 
et al., 2007). SCs were culture maintained in HAMF12 (EuroClone), supple-
mented with 0.166 nM retinoic acid (Sigma-Aldrich) and 5/500 ml of insulin-
transforming selenium (BD) in 95% air–CO2 at 37°C. Cells were extensively 
washed before use. In selected in vitro experiments, encapsulated hepatocytes 
or peripheral blood leukocytes from the same donors were used as a control to 
test for nonspecific effects of cell therapy, and none were found. Approx-
imately 120 × 106 cells are retrieved from neonatal pig testis pairs, and 20 × 106 
cells are required for reversing diabetes in a NOD mouse weighing 25 g.
IDO expression and functional analysis. IDO induction was investigated by 
immunoblotting with rabbit polyclonal anti–murine IDO antibody (Grohmann 
et al., 2007) or a monoclonal mouse anti–human IDO reagent (Millipore). 
Anti-actin AC-40 antibody (Sigma-Aldrich) was used as a normalizer in all as-
says. IDO functional activity was measured in vitro in terms of the ability to 
metabolize tryptophan to l-kynurenine, whose concentrations were measured 
by high-performance liquid chromatography (Romani et al., 2008a).
Vector construction and siRNA transfection. For silencing porcine IDO-
encoding mRNA expression, siRNA was cloned into pSUPER-puro (Oligo-
engine), and a construct was prepared, as previously described (Brummelkamp 
et al., 2002). Among several potential target sequences, a 19-nt gene-specific 
sequence was selected spanning nucleotides 344–363. After BLAST analysis 
to ensure lack of significant homology with other known Sus scrofa (pig) genes, 
the sequence was inserted into a BglII–HindIII-cut pSUPER-puro vector to 
generate the pSUPER-Ssc_IDOi vector. Freshly isolated SCs were trans-
fected with negative control pSUPER or pSUPER-Ssc_IDOi to obtain cells 
stably expressing siRNA, and stable integrants were selected by puromycin, 
starting 24 h after transfection. Negative control (null) pSUPER consisted of 
SC transfected with a sequence proven by BLAST analysis not to match any 
known S. scrofa sequence.
In brief, SCs were transfected with pSUPER or pSUPER-Ssc_IDOi 
vector by DOTAP liposomes (Roche). The plasmids were combined with 
DOTAP to form complexes to be used to transfect SC. 3 × 106 SCs were si-
lenced with 5 µg of plasmid DNA diluted to a concentration of 0.1 mg/ml 
in HBS buffer (Hepes-buffered saline: 20 mM HEPES, pH 7.4, containing 
150 mM NaCl; final volume, 50 µl) in a sterile tube. In a separate sterile 
tube, 30 µl DOTAP (1 mg/ml) was mixed with HBS buffer to a final vol-
ume of 100 µl. 50 µl of the DNA solution was transferred to the reaction 
tube already containing 100 µl DOTAP in HBS buffer and carefully mixed. 
The transfection (DOTAP–DNA) mixture was incubated for 30 min at 
room temperature. The mixture was gently added to 5 ml of SC cultures. 
The cells were then cultured for 48 or 72 h and inserted into the capsules to 
be administered in vivo. In parallel, the efficiency of IDO silencing was de-
termined by immunoblotting at the same time points.
PCR analyses. Real-time PCR (for Rorc, Tbet, Foxp3, Gata3, Pdx1, Ngn3, 
c-kit, Neurod1, Nkx6.1, Pax4, and Pax6) analyses were conducted as previously 
described (Romani et al., 2008a), using the primers listed in Table S1. Also 
shown in the table are primers designed to amplify S. scrofa mRNA predicted 
to encode porcine IDO, as revealed by multiple sequence alignment analysis 
(Fig. S4). Primers were designed according to the putative coding region.
Flow cytometry. In all FACS analyses, cells were treated with rat anti-
CD16/32 (2.4G2) for 30 min at 4°C for blockade of Fc receptors before assaying 
on an EPICS flow cytometer using EXPO 32 ADC software (Beckman 
Coulter). GITR and total CTLA-4 expressions were analyzed as previously 
described (Fallarino et al., 2003; Grohmann et al., 2007). For intracellular 
Foxp3, cells from PLNs were stained with anti–CD4 (GK1.5)-PE (BD), 
fixed, permeabilized, and stained with FITC-labeled anti-Foxp3 (FJK-16s; 
eBioscience) or isotype control rat IgG2a-FITC. Intracellular TGF- and 
IL-17A staining in sorted CD4+CD25+ and CD4+CD25 from the spleen 
was conducted as described upon overnight activation with 5 µg/ml of plate-
bound anti-CD3 (Romani et al., 2008a). For CFSE (Invitrogen) labeling, 
the fluorescent dye in the form of 5 mM of stock solution was added to 2 × 
106 CD4+CD25 T cells/ml to a final concentration of 2 µM. The cells 
were incubated at room temperature for 10 min and washed twice with an 
excess of FCS-enriched culture medium.
Fusion proteins. The following fusion proteins were used: murine proin-
sulin-related P3UmPI, murine GAD-related P3UmG, and human IA-2-
related P3UhIA, with recombinant OVA being the control protein. Purified 
CD4+CD25+ and CD4+CD25 cells were cultured for 3–5 d with fusion 
protein-pulsed splenic CD11c+ cells as antigen-presenting cells (5 µg/ml of 
fusion protein; overnight, in the presence of 5 µg/ml of purified mouse 2524 IDO+ SERTOLI CELLS REVERT AUTOIMMUNE DIABETES | Fallarino et al.
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IgG). The recovered T cells were assayed for intracellular cytokine produc-
tion, proliferation, and suppressive function.
Immunohistochemistry. In immunostaining for insulin, glucagon, and 
somatostatin, 4-µm sections were cut from paraffin blocks and captured on 
electrically charged slides (Sigma-Aldrich). Sections were dewaxed in xylene 
and stained with primary guinea pig anti–mouse insulin antibodies (Dako), 
FITC-labeled  mouse  anti–mouse  glucagon  monoclonal  (Sigma-Aldrich), 
and Alexa Fluor 555–labeled rabbit anti–mouse somatostatin antibody (Mil-
lipore) for 1 h at room temperature, washed in PBS, and incubated with a 
goat anti–guinea pig TRITC (tetramethyl rhodamine isothiocyanate) conju-
gate for 45 min (for insulin staining). Nuclei were counterstained with DAPI 
and mounted in DABCO (all from Sigma-Aldrich). In double immuno-
staining for Foxp3 and CD4, after dewaxing the sections, antigen retrieval 
was accomplished by microwave pressure cooking for 4 min at full pressure 
in 50 mM TRIS and 2 mM EDTA, pH 9. Slides were incubated for 1 h with 
primary  unconjugated  rat  anti–mouse  CD4  (Millipore)  and  Alexa  Fluor 
488–conjugated  anti–mouse  Foxp3  (150D;  BioLegend).  Sections  were 
washed with PBS and incubated with goat anti–rat TRITC conjugate for 45 
min (Millipore). Nuclei were counterstained with DAPI and mounted in 
DABCO. All slides were examined using a BX 41 apparatus in conjunction 
with F-View software (both from Olympus).
Statistical analysis. In the in vivo experiments, survival and glycemia data 
were analyzed by Kaplan-Meier plots. Paired data were evaluated by Student’s 
t test, and a one-way analysis of variance was used for multiple comparisons. 
All in vitro determinations are means ± SD from at least three independent 
experiments, unless otherwise indicated. All n values were computed by power 
analysis, so as to yield a power of at least 80% with an -level of 0.05.
Online supplemental material. Fig. S1 demonstrates that the effect of 
SC therapy is even more dramatic when SCs are administered to predia-
betic mice. Fig. S2 shows that diabetic mice rendered normoglycemic by SC 
therapy display nearly normal responses on intraperitoneal glucose testing. 
Fig. S3 deals with antigen specificity patterns of T reg cells induced by SC 
grafts in terms of proliferative responses to fusion proteins of proinsulin-
related P3UmPI, GAD-related P3UmG, and IA-2-related P3UhIA. Fig. S4 
depicts multiple amino acid sequence alignment of S. scrofa, Bos taurus, Homo 
sapiens, and Mus musculus IDOs. Fig. S5 provides data on IDO silencing ef-
ficiency in SC by immunoblot and immunofluorescence analyses. Fig. S6 
demonstrates that early proliferation of host residual  cells does not occur 
to a significant extent in NOD recipients of SC. Fig. S7 displays serum 
insulin levels at 6–8 wk of SC treatment, further confirming recovery of  
cell function. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20090134/DC1.
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